|View printer-friendly version|
|June 23, 2011 5:36 p.m.|
|Teva Comments on Supreme Court Decision|
|Jerusalem, Israel, June 23, 2011 - Teva is pleased with the High Court's decision today, which provides great clarity for both the drug industry as well as patients. This ruling reiterates that once the U.S. Food and Drug Administration approves a generic prescription drug as interchangeable to the brand, their labels must also be identical. Accordingly, generic companies do not have the ability to influence labeling and related information and should not be held liable for failing to do so.|
This is also a win for American consumers as they bear the ultimate burden of these lawsuits. The decision of the Supreme Court will help to alleviate unnecessary litigation.
Teva's top priority is the quality of our products and the safety of our patients.
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000
people around the world and reached $16.1 billion in net sales in 2010.